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Abstract  
Objective: To develop standardized treatment regimens for chronic nonbacterial 
osteomyelitis (CNO), also known as chronic recurrent multifocal osteomyelitis 
(CRMO) to enable comparative effectiveness treatment studies.  
Methods: Virtual and face-to-face discussions and meetings were held within the 
CNO subgroup of the Childhood Arthritis and Rheumatology Research Alliance 
(CARRA). A literature search was conducted, and CARRA membership was 
surveyed to evaluate available treatment data and identify current treatment 
practices. Nominal group technique was used to achieve consensus on treatment 
plans for CNO refractory to non-steroidal anti-inflammatory drug (NSAID) 
monotherapy and/or with active spinal lesions.  
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Results: Three consensus treatment plans (CTPs) were developed for the first 12 
months of therapy for CNO patients refractory to NSAID monotherapy and/or with 
active spinal lesions. The three CTPs are: (1) methotrexate or sulfasalazine, (2) 
tumor necrosis factor (TNF)-alpha inhibitors with optional use of methotrexate, and 
(3) bisphosphonates. Short courses of glucocorticoids and continuation of NSAIDs 
are permitted for all regimens. Consensus was achieved on these CTPs among 
CARRA members. Consensus was also reached on subject eligibility criteria, initial 
evaluations that should be conducted prior to the initiation of CTPs, and data items 
to collect to assess treatment response.  
 
Conclusion: Three consensus treatment plans were developed for pediatric patients 
with CNO refractory to NSAIDs and/or with active spinal lesions. Use of these CTPs 
will provide additional information on efficacy and will generate meaningful data for 
comparative effectiveness research in CNO.  
 
Significance and Innovations 
 Three standardized consensus treatment plans were developed for patients with 
CNO who have had insufficient response to NSAIDs and/or who have active 
spinal lesions.  
 The consensus treatment plans developed by members of the Childhood Arthritis 
and Rheumatology Research Alliance (CARRA) are the first ever for patients with 
CNO.  
 Use of these treatment plans will allow for evaluation of these medications in 
patients with CNO in future comparative effectiveness research studies. 
 
INTRODUCTION 
Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease that 
mainly affects children and adolescents. Clinical presentations range from mild and 
sometimes limited unifocal disease to severe, chronically active or recurrent 
inflammation of multiple bones. The latter is referred to as chronic recurrent 
multifocal osteomyelitis (CRMO). Here we will use the term “CNO” to refer to the 
entire spectrum of this disease. CNO can be complicated by vertebral compression 
fractures, kyphosis, and leg length discrepancy when it is not recognized early or 
treated adequately. The diagnosis of CNO is made by excluding alternatives in the 
differential diagnosis including malignancy (leukemia, lymphoma, and primary or 
metastatic bone tumors), Langerhans cell histiocytosis, and infection. Clinical 
assessment in conjunction with serum inflammatory parameters and imaging 
studies, particularly magnetic resonance imaging (MRI), are crucial for the diagnosis 
and monitoring of disease activity of CNO (1). 
Because of significant variation in clinical treatment practices among pediatric 
rheumatologists, standardized treatment regimens (consensus treatment plans, 
CTPs) have been developed within the Childhood Arthritis and Rheumatology 
Research Alliance (CARRA), a North American organization comprised of pediatric 
rheumatologists and researchers, for systemic juvenile idiopathic arthritis (JIA)  (2), 
polyarticular JIA  (3), lupus nephritis  (4), juvenile localized scleroderma  (5), and 
juvenile dermatomyositis  (6). These CTPs enable progress to be made towards 
identifying optimal treatment for these diseases through prospective observational 
studies. The developed CTPs were based on best available evidence and current 
treatment practices, and generated through consensus methodology including A
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nominal group techniques. The intention of these CTPs was to limit treatment 
practice variation to enable researchers to conduct comparative effectiveness 
studies. Because of the variability in second line treatment of CNO, we have worked 
to develop standardized treatment plans and data collection forms and measures for 
CNO patients with an NSAID-refractory course and/or with active spinal lesions. 
These CTPs will facilitate future comparative effectiveness studies for CNO. It must 
be noted that CTPs are not meant to be clinical care guidelines. A treating physician 
may deviate from the CTP at any time if it is deemed appropriate for the patient’s 
care. 
 
MATERIALS AND METHODS:  
The CARRA CNO work group of the CARRA Scleroderma, Vasculitis, 
Autoinflammatory and Rare Diseases (SVARD) subcommittee consists of board-
certified pediatric rheumatologists with special interest and expertise in CNO and 
family representatives. The CARRA CNO work group reviewed evidence published 
between 1966 and April 29, 2015. A literature search was conducted using Pubmed 
with the following MESH terms: SAPHO[All Fields] OR (Chronic[All Fields] AND 
nonbacterial[All Fields] AND ("osteomyelitis"[MeSH Terms] OR "osteomyelitis"[All 
Fields])) OR ("Chronic recurrent multifocal osteomyelitis"[Supplementary Concept] 
OR "Chronic recurrent multifocal osteomyelitis"[All Fields] OR "chronic recurrent 
multifocal osteomyelitis"[All Fields]) OR (noninfectious[All Fields] AND 
("osteomyelitis"[MeSH Terms] OR "osteomyelitis"[All Fields])) AND (hasabstract[text] 
AND "humans"[MeSH Terms] AND English[lang]). In total, 398 articles were 
screened. A complete list of literature is included in Supplement 1. There was no 
randomized controlled study or case-control study in CNO. Therefore, case series, 
historical cohort, and prospective observational studies with at least 3 months of 
follow-up data in the pediatric population were included for review. Twenty-one 
articles met the criteria. Eleven additional articles published between April 29, 2015 
and January 1, 2017 were later included. The group formulated clinical scenarios, 
analyzed survey responses from CNO workgroup members, organized consensus 
meetings, and finalized treatment plans. Levels evidence were graded from 2 to 5 
according to guidelines established by the Oxford Centre for Evidence-Based 
Medicine (CEBM; online at www.cebm.net). 
 
Planning meetings. Members of the CARRA CNO work group initiated the process 
to develop CTPs at the CARRA 2014 annual conference. Monthly conference calls 
within the work group were then used to develop a survey to CARRA members and 
ongoing discussion of the CTPs. The targeted population included patients refractory 
to NSAID monotherapy and/or with active spinal lesions because physicians 
perceived less favorable outcomes and need of additional treatment in such patients. 
At the planning meeting (Austin, TX, April 2015), a survey was sent to the SVARD 
subcommittee to collect responses of diagnostic, disease monitoring, and 
therapeutic approaches chosen by CARRA-affiliated pediatric rheumatologists. 
Further discussion at that meeting outlined the core substance of the planned CTPs. 
A detailed survey was sent to the CNO group (67% of 34 members responded) 
asking for comments on summarized plans and proposed options (see Supplement 
2). At the American College of Rheumatology annual conference (San Francisco, 
CA, 2015), a second meeting was attended by 13 pediatric rheumatologists. Patient 
characteristics, treatment options, and imaging monitoring were discussed in depth.  
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Consensus meetings. At the CARRA annual conference (Toronto, 2016), a CNO 
meeting was attended by 6 family representatives and 30 pediatric rheumatologists, 
one of whom acted as the facilitator (YZ). The facilitator and family representatives 
participated in the discussion but were not eligible to vote.  
 
Nominal group technique was used to achieve consensus (defined as ≥80% 
agreement within the group) on all questions considered during the meeting and 
subsequent conference calls. The facilitator framed the question to be discussed and 
presented data from the survey relevant to each question. Potential responses to the 
question were shown based on prior group discussion. Each participant had the 
opportunity to express his or her opinion for 1–2 minutes without interruption. 
Potential responses were updated accordingly.  
 
Participants were then given the opportunity to vote for their preferred responses to 
the questions using a show-of-hand vote.  Eighty percent or more of positive or 
negative votes was considered a consensus vote. If consensus was not achieved, 
participants were given the opportunity to speak uninterrupted for 1–2 minutes to 
share their thought process. After excluding answers that would not result in 
consensus votes, or after modifying potential responses, another vote was taken. If 
necessary, this process continued for two rounds on each question. If a clear 
consensus was not reached after two rounds, the decision was made to move to the 
next question.  
 
RESULTS 
 What standardized disease-assessment tools of CNO have been reported? 
Literature review of the clinical cohort studies on CRMO, CNO and pediatric 
synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome revealed a 
lack of agreement on a standardized evaluation tool. Two articles have reported 
standardized assessments with level IV evidence. Beck and colleagues used a 
PedCNO score (7) to assess prospectively the responses to naproxen in 37 children 
with CNO. After 12 months of treatment, 54% of patients achieved PedCNO 70 (at 
least 70% improvement in at least 3 out of 5 core variables and no more than one of 
remaining variables deteriorating by more than 70%). Within the core set, erythrocyte 
sedimentation rate (ESR), and the childhood health assessment questionnaire 
(CHAQ) had a floor effect by 3 months whereas the number of radiological lesions by 
MRI, severity of disease estimated by the physician, and severity of disease 
estimated by the patient or parent continued to improve over 12 months. Zhao and 
colleagues further described the characteristics of CNO lesions based on MRI 
findings using a grading system to score the severity of bone edema and soft tissue 
inflammation as well as the presence of periosteal reaction, hyperostosis, growth 
plate damage and vertebral compression (8). Applying this scoring tool to two 
retrospective cohorts of patients with CNO, authors found a significant decrease of 
number of nonvertebral lesions and maximum severity of bone edema in the group 
receiving aggressive treatment.  
 
What evidence of effectiveness of second-line treatments is there in CNO?  
Studies focusing on children with CNO who failed NSAID treatment are limited. 
Seven articles have reported treatment of pamidronate in CNO with level IV 
evidence. Kerrison and colleagues reported significant pain relief and improved 
activity and well-being with pamidronate use in seven children (three with spinal A
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lesions) who failed NSAIDs (9). Simm et al. (10) and Miettunen et al. (11) 
demonstrated the effectiveness of pamidronate in children with CNO refractory to 
NSAIDs. Greater than 80% of patients had pain relief and more than 90% of patients 
in Miettunen’s study exhibited resolution of bone lesions on MRI after six months of 
treatment. Gleeson and colleagues reported pain relief with pamidronate in six of 
seven children who failed NSAIDs (12). Among five children with spinal fractures, 
three had follow-up x-rays showing regression of height loss in affected vertebrae in 
response to pamidronate therapy. Hospach et al. (13) reported complete resolution 
of hyperintensity signal of active spinal lesions after three to six cycles of 
pamidronate and a median interval of 13 months follow-up with MRI in eight of nine 
children with CNO refractory to NSAIDs. Roderick et al. treated 11 children with CNO 
refractory to NSAIDs with four cycles of pamidronate at 1 mg/kg/day on three 
consecutive days every three months (14). Two patients exhibited a good response, 
six individuals showed a moderate response, one had a mild response, while two 
failed to respond based on repeated whole body MRIs. Schnabel et al. described 
pamidronate to be highly effective in CNO patients refractory to standard treatment 
with NSAIDs and/or glucocorticoids (15). 
 
Published data on the use of tumor necrosis factor (TNF)-alpha inhibitors (TNFi) in 
CNO are more limited. Eight articles have reported treatment of TNFi in CNO with 
level IV evidence. A small cohort study (n=4) reported by Eleftheriou et al. showed 
decreased pain in children with CNO after infliximab treatment (n=3) and anakinra 
(n=1, later switched to adalimumab) (16). Borzutzky et al. (17) and Wipff et al. (18) 
observed the highest rates of clinical remission (46%) or efficacy (89%) from TNFi 
compared to glucocorticoids, methotrexate, sulfasalazine, and NSAIDs. Jansson et 
al. (19), reported disease remission induced by infliximab in two patients who failed 
NSAIDs, glucocorticoids, DMARDs, and pamidronate. Recently, a combination of 
infliximab and methotrexate with or without zolendronic acid significantly improved 
clinical, laboratory, and imaging results in 9 children with CNO (8). However, Kaiser 
et al. showed poor response to TNFi in children with CNO in that only two of seven 
patients achieved remission (not defined) (20). On the other hand, etanercept was 
effective in all five patients in a small childhood series (21). Anti-interleukin (IL)-1 has 
been reported in fewer pediatric cases (20). In an adult cohort (n=6), anakinra 
improved the patient global assessment of disease activity within one month in five 
patients (22).  
Most literature reported variable success of methotrexate (MTX) and sulfasalazine 
(SSZ) in patients with poor responses to NSAIDs or frequent relapses. Other 
DMARDs were rarely used. Five articles have reported treatment of DMARDs in 
CNO with level IV evidence. Jansson et al. (19), Catalano et al.  (23), and Kaiser et 
al. (20) documented poor responses to SSZ, MTX, and azathioprine in children with 
CNO. Borzutzky et al. (17) and Wipff et al. (18) showed relatively lower remission 
rates (18-20%) and efficacy (38-41%) in children treated with MTX or SSZ. There 
was poor tolerance of MTX and dosing was not reported in most studies.  
 
Currently, there is no consensus on subsequent treatment for patients refractory to 
NSAID treatment. Based on a survey sent to members of CARRA, 95% of treating 
physicians responded (41% response rate) use NSAIDs as first-line treatment in A
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children with a new diagnosis of CNO (evidence level V) (24). For patients who failed 
NSAID treatment, the most commonly used treatments were reported as 
methotrexate (67%), TNFi (65%), and bisphosphonates (46%) (24). These results 
guided the development of consensus treatment plans (CTPs).  
What patient characteristics should be included for this CTP? 
Initial intent was to include all children with CNO. However, through further work 
group discussion, it was agreed that NSAIDs were generally considered first-line 
treatment for all newly diagnosed patients without active spinal lesions. Therefore, 
our attention turned to a more defined subset: patients refractory to NSAIDs and/or 
with active spinal lesions. The definition of “refractory to NSAID” was debated among 
group members, and the duration of initial NSAID trial was decided to be a minimum 
of 4 weeks. Based on the physician’s discretion and disease severity, further 
treatment may be initiated.  The rationale of including active spinal lesions as a 
patient characteristic is the perceived significance of increased risk of vertebral 
fracture  (11–13). The age limit for the CTP was set to 21 years, because children 
and adults younger than 21 years of age are commonly seen and followed in 
children’s hospitals. Patients with malignancy, infectious osteomyelitis, or other 
contraindications to the proposed treatment agents are not eligible for the CTP. 
Detailed characteristics of patients are provided in Table 1. 
 
What standardized data should be collected at the initial evaluation? 
Each patient should undergo a complete clinical assessment, including 
comprehensive musculoskeletal exam, since clinically active lesions are defined by 
findings of focal tenderness, and/or swelling, and/or warmth in addition to patient’s 
report of pain. Active joint counts with arthritis and enthesitis are important to record 
because of reported overlap between enthesitis-related arthritis (ERA) and CNO. 
Due to the lack of validated CNO-specific patient reported outcomes, both CHAQ 
and Patient-Reported Outcomes Measurement Information System (PROMIS) will be 
collected. Based on previously published diagnostic criteria of CNO  (19,25) and 
results from physician surveys  (24), a bone biopsy was recommended unless typical 
lesions including the clavicle or symmetrical lesions at metaphysis/epiphysis of long 
bones or comorbidities such as inflammatory bowel disease, palmoplantar 
pustulosis, or psoriasis are present. All participants agreed that whole body imaging 
is required to identify all bone lesions. Whole body MRI is preferred  (26). A 
suggested protocol is included in Table 1. Bone scintigraphy was considered an 
adequate alternative if whole body MRI is not available. Total number of bone 
lesions is recorded per radiologist’s report. A baseline MRI (whole body or regional) 
is required to define active bone lesions based on the presence of bone marrow 
edema from short tau inversion recovery (STIR) or T2 fat saturation sequences, as 
the MRI findings are important to guide treatment decisions and to monitor disease 
activity  (8,11,13,24,27). The normal range of bone marrow signal on MRI has not 
been established yet. Therefore, distinguishing abnormal marrow signal is subject to 
the experience of the radiologist reading the image. The size and severity of bone 
edema and/or soft tissue inflammation is determined by the radiologist based on 
previous description (8). Bony expansion, growth plate damage, and vertebral 
compression were considered disease damage and not active inflammation (8). In 
children who were treated with bisphosphonates, a linear hyperintense signal should 
not be mistaken as active lesions. Laboratory data including complete blood cell 
counts, ESR, and CRP are required for disease monitoring. Alkaline phosphatase at 
baseline is required to screen for metabolic bone disease. HLA-B27 has been A
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reported with association of cutaneous diseases in CNO and strong association with 
ERA. Thus, participants agreed to include HLA-B27 test.       
 
What are the most important therapies to include? 
We reviewed the literature for medications with reported efficacy in CNO refractory to 
NSAIDs, including non-biological disease modifying anti-rheumatic drugs (DMARDs), 
TNFi, and bisphosphonates  (8–14,17,18,20,28,29). There are no head-to-head 
comparisons among these treatments, even though current data suggested higher 
remission rates in children treated with TNFi than those with DMARDs  (17,18). 
Among physicians in CARRA, methotrexate, TNFi, and bisphosphonates were most 
commonly used after children with CNO failed NSAIDs  (24). Consensus was 
reached to include the three most commonly applied combinations of medications in 
final CTPs. There was a discussion on whether concomitant NSAIDs and/or oral 
glucocorticoid “bursts” were allowed. The group decided on the optional use of both 
with limits on the allowable duration of glucocorticoids due to their known side 
effects. Glucocorticoid “bursts” were defined as glucocorticoids (equivalent dosing of 
prednisone) up to 2 mg/kg/day (maximum daily dose of 60 mg) for up to a total of 6 
weeks of treatment with or without tapering. Chosen strategies were in agreement 
with current practice echoed by participants. In patients treated with TNFi, 
concomitant methotrexate was allowed to suppress formation of human anti-chimeric 
anti-TNF antibody production (particularly with infliximab) as well as for combination 
therapy (Table 2).  
 
What dose/route/frequency should be used for each medication in the CTPs? 
The most commonly used DMARD by physician members in the CARRA survey was 
methotrexate (34%) (24). However, within the CNO group, members reported that 
sulfasalazine was commonly used based on personal experiences. Thus, only these 
two DMARDs were included in the protocol. TNFi reported for use in CNO were 
limited to etanercept, adalimumab, and infliximab. The frequency of using these TNFi 
among surveyed CARRA physician members was 26% with adalimumab and 
infliximab, and 17% with etanercept (24). Thus, all 3 were included in the protocol. 
Other TNFi may be used by the treating physician with discretion.  Mandatory 
tuberculosis screening is required prior to the initiation of a TNFi. The dosing of 
DMARDs and TNFi followed standard JIA treatment regimens as reported in the 
literature and clinical practice (Table 2). Pamidronate was the most commonly 
reported bisphosphonate (9–15) whereas zolendronic acid was only reported as 
concomitant treatment in a single study (8). However, both were used by physicians 
within CARRA (pamidronate 79%, zolendronic acid 21%)  (24). Therefore, in the 
bisphosphonate arm, pamidronate and zolendronic acid were both included in the 
protocol. The dosing of bisphosphonates was based on the pediatric endocrinology 
literature and has been utilized in case series of CNO and SAPHO patients (Table 
2). Suggested toxicity monitoring and immunizations are included in Appendix 1. 
 
What criteria should be used to determine treatment failure?  
Various parameters have been used to define “treatment response” in CNO, 
including the PedCNO score (7), total number of clinically active bone lesions, and 
severity of bone edema and soft tissue inflammation on MRI (8). After discussion, 
group consensus was reached to use a composite score similar to the JIA core set 
based on significant variation of symptoms and a high incidence of pain amplification 
(pain in the absence of inflammatory activity) among CNO patients.  Various items A
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were proposed by group members and after in-depth discussion; the group identified 
the top 6 individual items. These treatment response criteria are considered as 
expert opinion (evidence level IV). Thereby, a modified composite score was 
proposed by replacing CHAQ and severity of disease estimated by patient or parent 
with the size and severity of bone marrow edema and/or soft tissue inflammation in 
the MRI and the total count of clinically active lesions. These criteria have not been 
validated and are merely suggestions for physicians to consider during their clinical 
management of children with CNO. As shown in Table 3, a combination of criteria for 
treatment failure include: patient pain as measured by visual analogue scale (VAS), 
total number of clinically active lesions (defined as focal tenderness, and/or swelling, 
and/or warmth in addition to patient’s report of pain at a known CNO lesion site), 
physician evaluation of disease activity as measured on a 10 centimeter Likert scale 
(VAS), number of radiological lesions by whole body MRI or bone scintigraphy, 
maximum severity of marrow edema of CNO lesions on imaging, and abnormal ESR 
and/or CRP after exclusion of other potential causes. The CHAQ was not included 
because of its floor effect and lack of applicability to the majority of CNO patients 
accordingly to CNO group members’ experience. Treatment failure at 3 months was 
defined as: no improvement in at least 4 of the 6 criteria, or no improvement in ≥ 
50% of applicable criteria if not all are available. Treatment success (complete 
resolution) was defined as resolution of pain, normalization of ESR and CRP, and 
resolution of marrow edema in MRI, reported previously  (17–19). 
 
Management of CNO patients at follow-up visits will depend on the overall 
assessment of disease activity by the physician because there are no validated 
criteria at this time. At the three-month follow-up visit, an escalation of treatment 
such as switching medications within an arm or switching to a different arm is 
recommended if there is worsening of the disease or no improvement based on the 
treating physician’s assessment (Figure 1). Otherwise, maintaining current treatment 
is recommended. With the exception of bisphosphonates (3-6 months), minimum 
treatment duration should be 12 months based on the chronic nature of CNO, poor 
response to previous NSAIDs treatment, and the risk of vertebral compression 
fractures. 
 
 
At what intervals should patients be followed for the purposes of data 
collection? 
Consensus was reached to follow intended CNO patients a minimum of every 3 
months for the first year. The follow-up visit may occur earlier if the physician has 
concerns about the clinical course and/or treatment response. In addition to routine 
history, physical exams and laboratories, MRI is strongly recommended to 
objectively assess disease activity at 6 and 12 months after adjusting therapy. 
Additional imaging is recommended in suspected disease flares or persistent activity 
despite treatment escalation. Whole body MRI is generally preferred, but regional 
MRI of known sites is acceptable in unifocal disease or if whole body MRI is not 
available.  
 
What data should be collected at follow-up? 
Consensus was reached to minimize data collection for practicability using a 
standardized form. Table 4 includes clinical parameters, imaging and laboratory 
tests considered essential for CNO follow-up assessment.  A
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Final approval of the CTP by CARRA members 
A final survey (Supplement 2) was sent to 337 active voting members of CARRA in 
April 2017. A total of 275 responses were received with a response rate of 82%. 
Among responders, 254 were attending pediatric rheumatologists in North America 
who have cared for children with CNO. Within these 254 responders, a total of 216 
(85%) completed the entire survey. Most responders (70%) had 1-4 patients with 
CNO who either failed NSAIDs or had active spinal lesions over the last 12 months 
whereas 14% had none and 16% had 5 or more. 
  
Survey results showed that greater than 90% of responders agreed with patient 
characteristics, treatment plans, and definition of treatment failure. Within the 
treatment plans, 78%, 90%, and 50% of 228 responders use DMARDs, TNFi, or 
bisphosphonates, respectively, on children who fail NSAIDs; 62%, 94%, and 73% of 
221 responders are willing to use these respective treatment plans on children with 
active spinal lesions.   
 
DISCUSSION 
To our knowledge, these are the first consensus treatment plans developed for 
children with CNO by members of a professional society. Our work demonstrates the 
feasibility of achieving consensus in treatment plans and data collection for a rare 
and under-studied pediatric rheumatic disease using a combination of surveys, a 
comprehensive literature search, and nominal group technique.  
 
Lack of validated criteria for classification and follow-up, as well as standardized 
treatment, has hindered the progress of comparative effectiveness research in CNO. 
Current approaches are solely based on small case series, personal experience, and 
expert opinion (1). Our work is one step forward towards standardizing applied 
treatment regimens based on existing data and collection of a minimal set of data. 
This may allow objective evaluation of the effectiveness of different treatments. In 
addition, consistent imaging data collection will provide important corroboration with 
patient reported outcomes and the physician’s clinical assessment.  
 
The CTPs presented here reflect current clinical practice of CARRA members. Thus, 
they are highly applicable and more likely to be adopted in daily practice by 
practitioners. The intent of these CTPs is to reduce the variation of applied treatment 
options so that meaningful data from as many patients as possible can be collected 
in an observational study.  
 
Of note, the proposed treatment plans are standardized regimens without strong 
evidence of which treatment is optimal. They are not to be misinterpreted as 
guidelines as their intention is to enable further study to identify optimal treatment. 
These CTPs currently do not include any biologic treatments other than TNFi, 
because of the rarity of their use in CNO and a lack of support by the available 
literature. However, these CTPs may be revised in the future to include other 
potentially effective forms of treatment as more evidence becomes available.  
 
Bone biopsy was not required for all children with CNO (18,25). However, other 
diagnoses must be excluded prior to using these plans based on the treating 
physician’s thorough evaluation. These plans should only be used when physicians 
are confident of the diagnosis.  A
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Since whole body MRI offers the most thorough imaging evaluation for CNO without 
exposure to radiation, it should be considered the gold standard. However, regional 
MRIs (or a series of multiple regional MRIs) are considered reasonable when whole 
body MRI is not available. Other whole body imaging, such as bone scintigraphy, is 
considered an alternative one-time baseline assessment whenever whole body MRI 
is not available. 
 
The CTP presented here has limitations. First, this CTP does not extend beyond 12 
months of treatment. Second, this CTP does not include biologic treatments other 
than TNFi. Third, validated disease monitoring scoring tools are lacking and the 
proposed criteria of treatment failure need further evaluation and validation.  
 
CONCLUSION 
 
Three standardized consensus treatment plans were developed for patients with 
CNO with insufficient response to NSAIDs and/or the presence of active spinal 
lesions. Use of these treatment plans will provide the opportunity to generate 
meaningful data for future prospective observational studies to evaluate their 
effectiveness in children with CNO. 
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Table 1. Patient characteristics for pediatric CNO refractory to NSAID monotherapy and/or 
with active spinal lesion 
Enrolled patients should have: 
Age at enrollment equal to or younger than 21 years  
Presence of bone edema on STIR or T2 fat saturation sequence on MRI within 12 
weeks of enrollment  
Whole body imaging evaluation (either WB MRI$ or bone scintigraphy)  
Active disease* after failing at least 4 weeks of NSAIDs and/or presence of active spinal 
lesions& regardless of NSAID trial 
Bone biopsy to exclude infection or malignancy unless bone lesions follow typical 
distribution# or there is IBD, psoriasis, or palmar plantar pustulosis  
 
Enrolled patients should not have: 
History of or current malignancy  
Current infectious osteomyelitis 
Contraindication to the selected treatment agent 
CNO: chronic nonbacterial osteomyelitis; NSAID: non-steroidal anti-inflammatory drug; 
STIR: short tau inversion recovery sequence; MRI: magnetic resonance imaging; WB: 
whole body; IBD: inflammatory bowel disease. 
$
 Suggested protocol includes STIR or fat saturation sequences of coronal views of 
whole body and sagittal view of total spine. Some patients may require dedicated views A
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of hands or feet when lesions in these areas are present. Gadolinium is not required. 
* Active disease is defined as persistent pain with focal tenderness and/or warmth 
and/or persistence of bone edema on MRI in at least one lesion site  
& Active spinal lesions are defined as bone edema within at least one vertebral body of 
the cervical, thoracic, or lumbar spine 
#
 Typical distribution of lesions include the clavicle or symmetrical lesions in long bones 
at metaphysis/epiphysis 
 
 
Table 2. Consensus treatment plans for the first 6-12 months 
Treatment A: Non-biological DMARDs
Methotrexate (oral or subcutaneous): 15 mg/m2 (maximum 25 mg/dose) weekly   
OR 
Sulfasalazine (oral): 50 mg/kg/day (maximum 1500 mg/dose) divided twice daily  
 
Treatment B: TNF-alpha inhibitors (TNFi) with or without methotrexate 
Adalimumab (subcutaneous): 20 mg every other week for body weight between 15-30 
kg; 40 mg every other week for body weight ≥ 30 kg. May increase to weekly. 
OR 
Etanercept (subcutaneous): 0.8 mg/kg (maximum 50 mg/dose) weekly. May split into 
twice a week.  
OR 
Infliximab (intravenous): 5-10 mg/kg (maximum 1000 mg/dose) at week 0,2,6 then every 
4-8 weeks 
OR   
Other TNFi as per discretion of treating physician 
Optional: concomitant methotrexate (do not need to follow treatment protocol, may use 
lower dosing, i.e. 5-10 mg/m2) 
Treatment C: Bisphosphonate 
Pamidronate (intravenous)*:  
Option 1: 1 mg/kg/dose (maximum 60 mg/dose) every month 
Option 2: 1 mg/kg/dose for 3 consecutive days every 3 months 
OR 
Zolendronic acid (intravenous): Initial dose 0.0125- 0.025 mg/kg every 6 months. May 
increase dose to 0.05 mg/kg/dose (maximum 4 mg/dose) 
 
All options allow concurrent use of  
NSAIDs (see appendix for detailed dosing)  
Glucocorticoids: Up to a total of 6 weeks of treatment with or without tapering with an 
upper limit of 2 mg/kg/day (equivalent dosing of prednisone, maximum 60 mg daily). A
cc
ep
te
d 
A
rt
ic
le
A
cc
ep
te
d 
A
rt
ic
le
 
 
 
 
 
 
  
 
 
 
 
 
 
This article is protected by copyright. All rights reserved. 
 
DMARD: disease modifying anti-rheumatic drug; TNF: tumor necrosis factor; NSAID: 
non-steroidal anti-inflammatory drug. With the exception of bisphosphonates (3-6 
months), minimum treatment duration should be 12 months. 
* Both options may use lower dose of 0.5 mg/kg at the initiation of the treatment. Both 
options should continue for a minimum duration of 3 months. Maximum cumulative dose 
is 11.5 mg/kg/year.  
 
 
Table 3. Criteria for treatment failure at 3 months (when a patient fails to improve on at least 
4/6 of the criteria or over 50% of applicable criteria)  
 
1) Patient pain as measured by VAS  
2) Total number of clinically active lesions& 
3) Number of radiological lesions by WBMRI or bone scintigraphy  
4) Size and degree of marrow edema of CNO lesions and/or presence of soft tissue 
swelling/inflammation related to CNO lesion on imaging 
5) Physician VAS  
6) Abnormal ESR and/or CRP after exclusion of other potential causes*  
VAS: visual analogue scale: CNO: chronic nonbacterial osteomyelitis; WBMRI: whole 
body magnetic resonance imaging; ESR: erythrocyte sedimentation rate; CRP: C- 
reactive protein.  
& Clinically active lesion is defined as a body part with focal tenderness, and/or swelling, 
and/or warmth in addition to patient’s report of pain at a known CNO lesion site. 
* Abnormal ESR is defined as ≥20 mm/hr and abnormal CRP is defined as ≥1 mg/dL. 
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Table 4. Suggested minimum data collection and assessment intervals to be used with treatment 
plans* 
Proposed variables   
Baseline 
visit  
Follow up 
visits 
History    
    Demographics     
        Date of birth   x   
        Sex   x   
        Race and ethnicity   x   
    Clinical symptoms     
        Fever   x  x 
        Rash   x  x 
        Gastroenterological symptoms  x  x 
        Bone pain  x  x 
        Limitation of motor function$  x  x 
    Pre-enrollment treatment history for CNO  x   
    Family history of CNO-associated conditions#  x   
    Past medical history/concurrently CNO-associated conditions# x  x 
    Current medications and doses   x  x 
Patient-reported outcomes and global assessments     
    Pain   x  x 
    Health-related quality of life   x  x 
    Physical function –CHAQ, PROMIS   x  x 
    Parent/patient global assessment of disease activity    x  x 
    Physician global assessment of disease activity   x  x 
Physical examination    
    Height, weight   x  x 
    Clinically active CNO lesion count  x  x 
    Active joint counts                                                             x  x 
    Enthesitis  x  x 
    Rash    x  x 
Imaging findings     
    MRI (whole body preferred if available)  x  x 
    Bone scintigraphy if WB MRI is not available  x   
    X ray if done   x  x 
    CT if done  x  x 
    DXA if done  x  x 
Laboratory findings     
    CBC with differential  x  x 
    C-reactive protein    x  x 
    Erythrocyte sedimentation rate    x  x 
    Alkaline Phosphatase  x   
    HLA-B27  x   
Bone biopsy findings&     
    Bacterial, fungal and AFB culture  x   
    Pathology  x   A
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Treatment plan–related items     
    Serious adverse events or important medical event  x
    If plan discontinued, rationale    x 
    Number of glucocorticoid burst, if any  x
*Data are collected at baseline and at follow up visits every 2-3 months.  
CNO: chronic nonbacterial osteomyelitis; MRI: magnetic resonance imaging; CT: computed 
tomography; DXA: dual energy X ray absorptiometry; CBC: complete blood cell count; HLA: 
human leukocyte antigen. 
$Prolonged school/daycare absences, limited use of upper limb, difficulty weight bearing, requiring 
crutches, bedridden from spinal/leg pain. 
#Psoriasis, inflammatory bowel disease, celiac disease, inflammatory arthritis, spondyloarthropathy 
&Needed when bone lesions do not follow typical distribution (clavicle or symmetrical lesions in 
long bones at metaphysis/epiphysis) in the absence of CNO-associated conditions. 
 
Figure 1. Summary of protocols 
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Appendix 1 
Medication Dosing and Monitoring for CNO CTPs 
Nonsteroidal anti-inflammatory drugs (NSAIDs)  
A. Dose (1) 
• Celecoxib (age 2 and older): 10-25 kg: 100 mg/dose twice daily; > 25 kg: 200 
mg/dose twice daily 
• Diclofenac: 2-3 mg/kg/day divided 3 times per day, maximum 150 mg/day  (2) 
• Ibuprofen: 30-40mg/kg/day divided 3 times per day, maximum 3200 mg/day 
• Indomethacin: 1-3 mg/kg/day divided 2-3 times per day, maximum 200 mg/day  (3) 
• Meloxicam: 0.125-0.25 mg/kg/day once daily, maximum 15 mg/day 
• Naproxen: 10-20 mg/kg/day divided 2 times per day, maximum 1000 mg/day  (4–7) 
• Piroxicam: 0.2-0.3 mg/kg/day once daily, maximum 20 mg/day 
B. Toxicity monitoring 
• Check CBC with differential, serum creatinine, and liver enzymes prior to initiation 
and every 6 months during chronic daily use  (8) 
C.  Other recommendations 
• Take with food 
• Do not combine with other NSAIDs 
• Avoid in patients with renal dysfunction, thrombocytopenia, liver dysfunction 
D.  Side effects to capture:  gastritis or gastric ulcer, hepatic or renal toxicity, 
pseudoporphyria 
  
Glucocorticoids 
A. Dose 
Glucocorticoids (equivalent dosing of prednisone) up to 2 mg/kg/day with maximum daily 
dose of 60 mg for up to 6 weeks with or without tapering are allowed for flares 
B. Toxicity monitoring A
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•    Not necessary unless patient has diabetes or hypertension  
C.  Other recommendations 
•   Take in the morning to reduce sleep disturbance and other side effects 
•    Dietary guidance to reduce the risk of weight gain 
D.  Side effects to capture: weight gain, infection, acne, hirsutism, behavioral changes  
 
Non-Biologic DMARDs  (9) 
Methotrexate (MTX) 
A. Route 
• Oral or subcutaneous dosing allowed (reminder that subcutaneous route may have fewer 
side effects, better absorption, and improved efficacy at doses greater than 10 mg/m2)  
B. Dose  (10) 
• Recommended dosing: 15 mg/m2/week  
• Maximum recommended dose at any time: 25 mg 
C. Toxicity monitoring 
• Check CBC with differential, LFTs (AST, ALT), and creatinine prior to initiation, 
approximately 1 month after initiation, approximately 1-2 months after an increase in 
dose, repeat every 3-4 months if prior results are normal and dose is stable 
• Folic acid and/or leucovorin is recommended 
• Consider hepatitis A, hepatitis B, hepatitis C, and/or varicella screening at baseline 
• Consider PPD or interferon gamma release assay prior to starting 
• Interferon gamma release assay may not be a reliable assay in children < 2 years of age 
or children on glucocorticoid therapy 
D. Side effects to capture: fatigue, headache, neurologic affects, nausea, vomiting, and 
abdominal pain 
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Sulfasalazine (SSZ) 
A. Dosing 
• Recommended dosing: 50 mg/kg/day up to 3 grams/day 
B. Toxicity monitoring:  
• Check CBC with differential, LFTs (AST, ALT) and creatinine prior to initiation, 
approximately 1 month after initiation, approximately 1-2 months after an increase in 
dose, repeat every 3-4 months if prior results are normal and dose is stable 
• Consider hepatitis B screening at baseline 
• Reminder that hemolytic anemia (associated with glucose-6-phosphate dehydrogenase 
deficiency), Stevens Johnson Syndrome, and DRESS syndrome* have been reported in 
patients taking SSZ 
*DRESS syndrome – Rash, eosinophilia, and at least one of the following: enlarged lymph 
nodes, hepatitis (transaminases or AST, ALT >2X upper limit of normal), interstitial 
nephropathy, lung disease or myocardial involvement 
 
Tumor necrosis factor (TNF)-α inhibitors  (9) 
A. Dosing  
• Etanercept: 0.8 mg/kg SQ weekly or divided twice weekly, maximum 50 mg per week 
• Infliximab: 5-10 mg/kg IV 0, 2, 6 weeks and then every 4-8 weeks  (10,11) 
• Adalimumab: 15-30 kg: 20 mg SQ every other week, may increase to every week; ≥ 30 
kg: 40 mg SQ every other week, may increase to every week  (11) 
• Other TNF-α inhibitor use and dosing are subject to the discretion of treating physician 
• Concomitant methotrexate (do not need to follow treatment protocol, may use lower 
dosing) 
B. Toxicity Monitoring  
• Check CBC with differential, liver enzymes, serum creatinine prior to initiation, repeat 
approximately every 3- 6 months if prior results normal and dose stable A
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• PPD or interferon gamma release assay prior to initiation, repeat approximately once 
yearly if risk factors present. If positive, need chest X ray and treatment per infectious 
diseases prior to initiating treatment (usually at least 4-6 weeks of treatment) 
• Interferon gamma release assay may not be a reliable assay in children < 2 years of age 
or children on glucocorticoid therapy 
• Consider screening for histoplasmosis, blastomycosis, coccidiomycosis in endemic 
areas  
C. Other recommendations  
• Avoid live virus vaccinations while on biologic agents 
• Avoid combinations of biologic agents 
• Recommend discussion of the FDA malignancy risk warning as part of routine 
counseling prior to initiation of therapy  
• Methotrexate use is recommended but not required with infliximab to avoid human 
antichimeric antibody development 
 
Bisphosphonates  
A. Route – intravenous administration 
B. Dose 
1.  Pamidronate: 
Option 1: 1 mg/kg/dose (maximum 60 mg/dose) every month  (12) 
Option 2: 1 mg/kg/dose (maximum 60 mg/dose) for 3 consecutive days every 3 months  (13–
18) 
• Both options may use lower dose of 0.5 mg/kg at the initiation of the treatment 
• Both options should continue for a minimum duration of 3 months. Maximum 
cumulative dose is 11.5 mg/kg/year 
2. Zolendronic acid: 
Initial dose at 0.0125- 0.025 mg/kg every 3-6 months. May increase dose to 0.05 
mg/kg/dose (maximum 4 mg/dose) per (10,19,20)  
C. Toxicity monitoring 
• Check electrolytes, calcium, phosphate, magnesium, and creatinine prior to each 
monthly infusion or the first day of three consecutive infusions  A
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D. Other recommendations 
• Consider Zofran as pre-medications and use for post-infusion nausea  
• Daily Calcium and vitamin D supplementation  
• Baseline dental evaluation and regular dental care are recommended 
• Avoid dental extraction per dentist’s recommendation 
• Discussion of fetal risk with female patients  (21) 
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